An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
Approximately 386,000 shares were liquidated for a total transaction value of $8.5 million on July 2, 2026. This transaction consisted entirely of directly held shares.
ADPT - Adaptive Biotechnologies Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.25
DETAILS
HIGH:
$22.00
LOW:
$20.00
MEDIAN:
$21.50
CONSENSUS:
$21.25
DOWNSIDE:
7.29%
Stock News
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2026 after market close on Wednesday, July 29, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Adaptive Biotechnologies Business Separation May Unlock Greater Value
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce potential dilution Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $250 million aggregate principal amount of notes.
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading higher during Tuesday's session as the company has announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Adaptive Biotechnologies plans separation of immune medicine platform
Adaptive Biotechnologies said on Monday it planned to separate its immune medicine business from its residual cancer-testing unit, as it reviews options for the drug-discovery business and focuses on testing.
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilution Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Adaptive Biotechnologies also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes.
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
Chief People Officer Francis Lo disposed of 39,741 Common Stock shares on June 4, 2026, for a total transaction value of ~$695,000 based on a weighted average price of $17.49 per share. The transaction represented 13.56% of Lo's direct holdings at the time of execution, reducing direct ownership to 250,934 shares.
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
Adaptive Biotechnologies NASDAQ: ADPT Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair's Growth Stock Conference.
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm.
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.2 per share a year ago.
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026. “We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development.
Price Targets
Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley
$20.00
(was $20.16)
Morgan Stanley
Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim
$22.00
(was $20.96)
Guggenheim
Adaptive Biotechnologies price target raised to $22 from $21 at BTIG
$22.00
(was $16.47)
BTIG
Adaptive Biotechnologies price target raised to $21 from $20 at JPMorgan
$21.00
(was $16.47)
Sebastian Sandler
·
Piper Sandler
Adaptive Biotechnologies price target raised to $21 from $20 at Guggenheim
$21.00
(was $18.91)
Guggenheim
Adaptive Biotechnologies assumed with an Equal Weight at Morgan Stanley
$21.00
(was $18.84)
Kallum Titchmarsh
·
Morgan Stanley
Adaptive Biotechnologies price target raised to $20 from $15 at Piper Sandler
$20.00
(was $16.28)
Piper Sandler
Guggenheim starts Adaptive with Buy on cancer test leadership
$20.00
(was $13.46)
Guggenheim
Adeptus Biotechnologies Corp. (ADPT) PT Lowered to $5 at BTIG, 'assign a lower valuation to the businesses'
$5.00
(was $2.68)
Mark Massaro
·
BTIG
Adaptive Biotechnologies upgraded to Overweight from Neutral at Piper Sandler
$14.00
(was $7.09)
David Westenberg
·
Piper Sandler
Adaptive Biotechnologies price target raised to $12 from $7.50 at Piper Sandler
$12.00
(was $11.55)
David Westenberg
·
Piper Sandler
Adaptive Biotechnologies (ADPT) Stock Price: $7.50 Target From Piper Sandler
$7.50
(was $6.97)
David Westenberg
·
Piper Sandler
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $18
$18.00
(was $8.15)
Morgan Stanley